Hypertension in Obesity

Medical Clinics of North America

Volumn 95, Issue 5, 2011, Pages 903-917

  Kurukulasuriya, L Romayne ^a   Stas, Sameer ^a   Lastra, Guido ^a   Manrique, Camila ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

Author keywords

Adipocyte; Cardiovascular disease; Chronic kidney disease; Hypertension; Insulin resistance; Obesity

Indexed keywords

ADIPONECTIN; ENDOTHELIN 1; FATTY ACID; GLUCOCORTICOID; LEPTIN;

ADIPOCYTE; ADRENERGIC SYSTEM; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; ENVIRONMENTAL FACTOR; ETHNICITY; HEREDITY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE;

ADIPOCYTES; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; OBESITY; RENIN-ANGIOTENSIN SYSTEM; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM;

EID: 80051771011     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.06.004     Document Type: Review

References (90)

1. Canoy D., Luben R., Welch A., et al. Fat distribution, body mass index and blood pressure in 22,090 men and women in the Norfolk cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) study. J Hypertens 2004, 22(11):2067-2074.
2. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003, 290(2):199-206.
3. Flack J.M., Casciano R., Casciano J., et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 2002, 15(11):28-36.
4. Must A., Spadano J., Coakley E.H., et al. The disease burden associated with overweight and obesity. JAMA 1999, 282(16):1523-1529.
5. Narkiewicz K. Diagnosis and management of hypertension in obesity. Obes Rev 2006, 7(2):155-162.
6. Cooper R., McFarlane-Anderson N., Bennett F.I., et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens 1997, 11(2):107-111.
7. Engeli S., Böhnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45(3):356-362.
8. Massiera F., Bloch-Faure M., Ceiler D., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15(14):2727-2729.
9. Hall J.E., Brands M.W., Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 1999, 892:91-107.
10. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr Res 1998, 24(3/4):789-796.
11. Rahmouni K., Correia M.L., Haynes W.G., et al. Obesity induced hypertension: new insights into mechanism. Hypertension 2005, 45(1):9-14.
12. Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese patients with hypertension (TROPHY) study group. Hypertension 1997, 30(1 Pt 1):140-145.
13. De Paula R.B., Da Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43(1):41-47.
14. Davy K.P., Hall J.E. Obesity and hypertension: two epidemics or one?. Am J Physiol Regul Integr Comp Physiol 2004, 286(5):R803-R813.
15. Alvarez G.E., Beske S.D., Ballard T.P., et al. Sympathetic neural activation in visceral obesity. Circulation 2002, 106(20):2533-2536.
16. Alvarez G., Ballard T., Beske S., et al. Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol 2004, 287(1):H14-H18.
17. Rumantir M.S., Vaz M., Jennings G.L., et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999, 17(8):1125-1133.
18. Weyer C., Pratley R.E., Snitker S., et al. Ethnic differences in insulinemia and sympathetic tone as links between obesity and hypertension. Hypertension 2000, 36(4):531-537.
19. Wofford M.R., Anderson D.C., Brown C.A., et al. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14(7 Pt 1):694-698.
20. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14(3):173-194.
21. Modan M., Halkin H., Almog S., et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985, 75(3):809-817.
22. Hall J.E., Brands M.W., Zappe D.H., et al. Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin resistant dogs. Hypertension 1995, 25(5):994-1002.
23. Anderson E.A., Hoffman R.P., Balon T.W., et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87(6):2246-2252.
24. Sawicki P.T., Baba T., Berger M., et al. Normal blood pressure in patients with insulinoma despite hyperinsulinemia and insulin resistance. J Am Soc Nephrol 1992, 3(Suppl 4):S64-S68.
25. Reaven G.M., Chang H. Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens 1991, 4(1 Pt 1):34-38.
26. Sechi L.A., Melis A., Tedde R. Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism 1992, 41(11):1261-1266.
27. McFarlane S.I., Banerji M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86(2):713-718.
28. Grunfeld B., Balzareti H., Romo H., et al. Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994, 23(Suppl 1):I12-I15.
29. Beatty O.L., Harper R., Sheridan B., et al. Insulin resistance in offspring of hypertensive parents. BMJ 1993, 307(6896):92-96.
30. Hall J.E., Brands M.W., Henegar J.R., et al. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharmacol Physiol 1998, 25(1):58-64.
31. Kambham N., Markowitz G.S., Valeri A.M., et al. Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59(4):1498-1509.
32. Bloomfield G.L., Sugerman H.J., Blocher C.R., et al. Chronically increased intra-abdominal pressure produces systemic hypertension in dogs. Int J Obes Relat Metab Disord 2000, 24(7):819-824.
33. Aneja A., El-Atat F., McFarlane S., et al. Hypertension and obesity. Recent Prog Horm Res 2004, 59:169-205.
34. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr Opin Nephrol Hypertens 2006, 15(2):173-178.
35. Lofgren P., Andersson I., Adolfsson B., et al. Long-term prospective and controlled studies demonstrate adipose tissue hypercellularity and relative leptin deficiency in the postobese state. J Clin Endocrinol Metab 2005, 90(11):6207-6213.
36. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003, 100(24):14211-14216.
37. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
38. Tan M.S., Chang S.Y., Chang D.M., et al. Association of resistin gene 3'-untranslated region +62G→A polymorphism with type 2 diabetes and hypertension in a Chinese population. J Clin Endocrinol Metab 2003, 88(3):1258-1263.
39. Zhang J., Qin Y., Zheng X., et al. [The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure]. Chung-Hua i Hsueh Tsa Chih. [Chinese Medical Journal] 2002, 82(23):1609-1612. [in Chinese].
40. Asai T., Ohkubo T., Katsuya T., et al. Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects. Hypertension 2001, 38(6):1321-1324.
41. Cardillo C., Campia U., Iantorno M., et al. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004, 43(1):36-40.
42. Tiret L., Poirier O., Hallet V., et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999, 33(5):1169-1174.
43. Mather K.J., Lteif A., Steinberg H., et al. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004, 53(8):2060-2066.
44. Grekin R.J., Vollmer A.P., Sider R.S. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 1995, 26(1):193-198.
45. Sarafidis P.A., Bakris G.L. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. J Hum Hypertens 2007, 21(1):12-19.
46. Bujalska I.J., Kumar S., Stewart P.M. Does central obesity reflect " Cushing's disease of the omentum" ?. Lancet 1997, 349(9060):1210-1213.
47. Sukhija R., Kakar P., Mehta V., et al. Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension. Am J Cardiol 2006, 98(4):544-548.
48. Ferrari P., Lovati E., Frey F.J. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J Hypertens 2000, 18(3):241-248.
49. Masuzaki H., Yamamoto H., Kenyon C.J., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003, 112(1):83-90.
50. Haynes W.G., Morgan D.A., Walsh S.A., et al. Receptor mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100(2):270-278.
51. Münzberg H., Björnholm M., Bates S.H., et al. Leptin receptor action and mechanisms of leptin resistance. Cell Mol Life Sci 2005, 62(6):642-652.
52. Wallace A.M., McMahon A.D., Packard C.J., et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Cornary Prevention Study (WOSCOPS). Circulation 2001, 104(25):3052-3056.
53. Mark A.L., Correia M.L., Rahmouni K., et al. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002, 20(7):1245-1250.
54. Yang R., Barouch L.A. Leptin signaling and obesity: cardiovascular consequences. Circ Res 2007, 101(6):545-559.
55. Katagiri H., Yamada T., Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007, 101(1):27-39.
56. Vecchione C., Aretini A., Maffei A., et al. Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension 2003, 42(2):166-170.
57. Dunbar J.C., Hu Y., Lu H. Intracerebroventricular leptin increases lumbarand renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997, 46(12):2040-2043.
58. Shek E.W., Brands M.W., Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31(1 Pt 2):409-414.
59. Quehenberger P., Exner M., Sunder-Plassmann R., et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002, 90(6):711-718.
60. Bouloumie A., Marumo T., Lafontan M., et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13(10):1231-1238.
61. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(3):439-451.
62. Adamczak M., Wiecek A., Funahashi T., et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003, 16(1):72-75.
63. Francischetti E.A., Celoria B.M., Duarte S.F., et al. Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals. Metabolism 2007, 56(11):1464-1469.
64. Iwashima Y., Katsuya T., Ishikawa K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43(6):1318-1323.
65. Chow W.S., Cheung B.M., Tso A.W., et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007, 49(6):1455-1461.
66. Schillaci G., Pirro M. Hypoadiponectinemia: a novel link between obesity and hypertension?. Hypertension 2007, 49(6):1217-1219.
67. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116(7):1784-1792.
68. Ohashi K., Kihara S., Ouchi N., et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47(6):1108-1116.
69. Chen H., Montagnani M., Funahashi T., et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278(45):45021-45026.
70. Motoshima H., Wu X., Mahadev K., et al. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004, 315(2):264-271.
71. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42(3):231-234.
72. Clasen R., Schupp M., Foryst-Ludwig A., et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005, 46(1):137-143.
73. Baguet J.P., Narkiewicz K., Mallion J.M. Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens 2006, 24(1):205-208.
74. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342(19):1378-1384.
75. Davies R.J., Crosby J., Vardi-Visy K., et al. Non-invasive beat to beat arterial blood pressure during non-REM sleep in obstructive sleep apnoea and snoring. Thorax 1994, 49(4):335-339.
76. Dimsdale J.E., Coy T., Ziegler M.G., et al. The effect of sleep apnea on plasma and urinary catecholamines. Sleep 1995, 18(5):377-381.
77. Narkiewicz K., Pesek C.A., Kato M., et al. Baroreflex control of sympathetic activity and heart rate in obstructive sleep apnea. Hypertension 1998, 32(6):1039-1043.
78. Robinson G.V., Stradling J.R., Davies R.J. Sleep 6: obstructive sleep apnea/hypopnea syndrome and hypertension. Thorax 2004, 59(12):1089-1094.
79. Lesske J., Fletcher E.C., Bao G., et al. Hypertension caused by chronic intermittent hypoxia-influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997, 15(12 Pt 2):1593-1603.
80. Carlson J.T., Hedner J.A., Sellgren J., et al. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med 1996, 154(5):1490-1496.
81. Kato M., Roberts-Thomson P., Phillips B.G., et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000, 102(21):2607-2610.
82. Duchna H.W., Stoohs R., Guilleminault C., et al. Vascular endothelial dysfunction in patients with mild obstructive sleep apnea syndrome. Wien Med Wochenschr 2006, 156(21/22):596-604.
83. Gjorup P.H., Sadauskiene L., Wessels J., et al. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea: relation to blood pressure and severity of disease. Am J Hypertens 2007, 20(1):44-52.
84. Phillipps B.G., Narkiewicz K., Pesek C.A., et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999, 17(1):61-66.
85. Moller D.S., Lind P., Strunge B., et al. Abnormal vasoactive hormones and 24-hour blood pressure in obstructive sleep apnea. Am J Hypertens 2003, 16(4):274-280.
86. Fletcher E.C., Bao G., Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999, 34(2):309-314.
87. Zhang X.L., Yin K.S., Wang H., et al. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 2006, 73(1):73-77.
88. Makino S., Handa H., Suzukawa K., et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006, 64(1):12-19.
89. Masserini B., Morpurgo P.S., Donadio F., et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 2006, 29(8):700-705.
90. Zhang X.L., Yin K.S., Li C., et al. Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J (Engl) 2007, 120(17):1477-1481.